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Abstract
Gold nanoparticle-mediated photothermal therapy (PTT) has shown great potential for the treatment of cancer in
mouse studies and is now being evaluated in clinical trials. For this therapy, gold nanoparticles (AuNPs) are
injected intravenously and are allowed to accumulate within the tumor via the enhanced permeability and
retention (EPR) effect. The tumor is then irradiated with a near infrared laser, whose energy is absorbed by the
AuNPs and translated into heat. While reliance on the EPR effect for tumor targeting has proven adequate for
vascularized tumors in small animal models, the efficiency and specificity of tumor delivery in vivo, particularly in
tumors with poor blood supply, has proven challenging. In this study, we examine whether human T cells can be
used as cellular delivery vehicles for AuNP transport into tumors. We first demonstrate that T cells can be efficiently
loaded with 45 nm gold colloid nanoparticles without affecting viability or function (e.g. migration and cytokine
production). Using a human tumor xenograft mouse model, we next demonstrate that AuNP-loaded T cells retain
their capacity to migrate to tumor sites in vivo. In addition, the efficiency of AuNP delivery to tumors in vivo is
increased by more than four-fold compared to injection of free PEGylated AuNPs and the use of the T cell delivery
system also dramatically alters the overall nanoparticle biodistribution. Thus, the use of T cell chaperones for AuNP
delivery could enhance the efficacy of nanoparticle-based therapies and imaging applications by increasing AuNP
tumor accumulation.
Introduction
Gold nanoparticles (AuNPs) have been successfully used
to enable photothermal therapy (PTT) for the treatment
of cancer in small animal studies [1-5], and has recently
moved towards clinical application [6]. A variety of
AuNPs have been examined for PTT, including silica-
gold nanoshells [2], gold nanorods [7], gold nanocages
[8], gold-gold sulfide nanoparticles [9], and hollow gold
nanoshells [3]. These particles can be engineered to
absorb light in the near infrared (NIR) range, where
light is maximally transmissive and minimally absorbed
by tissue. AuNP delivery can be accomplished by sys-
temic administration (intravenous injection). The nano-
particles, depending on their shape, hydrodynamic size,
and surface charge, will accumulate within the tumor
via its irregular vasculature; this passive accumulation is
known as the enhanced permeability and retention
(EPR) effect [10,11]. Polyethylene glycol (PEG)-coated
particles with a hydrodynamic diameter of approxi-
mately 60 nm have demonstrated the most efficient
delivery to the tumor using the EPR effect [11], and
more recently, the use of smaller hollow gold [3] and
gold-gold sulfide nanoshells [12] (20-40 nm diameter)
has further improved nanoparticle half-life in the blood.
However, even with these smaller particles, the percen-
tage of the injected dose (ID) delivered to the tumor is
low [13,14], and accumulation in non-target sites such
as the liver and spleen is comparatively high [13,15].
Thus, new methods aimed at improving tumor delivery
and specificity may increase the tumor concentration of
gold nanoparticles and ultimately the efficacy of anti-
tumor PTT and enhance nanoparticle mediated imaging
techniques.
Attempts at augmenting gold nanoparticle tumor
delivery have included a variety of nanoparticle surface
modifications, including conjugation with antibodies [3]
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ing ligands has only modestly improved tumor accumu-
lation and specificity. This is likely due to the reliance
of these nanoparticles on passive accumulation through
EPR, which is highly dependent on adequate blood flow
to the tumor. Therefore, tumors or tumor regions that
exhibit poor vasculature and hypoxia are less likely to
be effectively targeted using nanoparticles, ultimately
limiting their therapeutic use. Choi et al. [17] recently
demonstrated that macrophages could be used as a cel-
lular delivery vehicle to deposit AuNPs in tumors and
hypoxic tumor tissues, facilitating delivery through
active cellular migration and extravasation in response
to chemotactic factors produced by malignant cells.
These encouraging results suggested that other immune
cells might be used as cellular delivery vehicles. In this
study, we assessed the capacity of activated T cells to
function as chaperones for AuNPs. Unlike macrophage,
T cells are readily isolated and expanded in vitro,a n d
upon infusion, circulate throughout the body and
migrate into tumors in response to tumor-associated
chemokines. This tumor-tropic property permits their
use as cellular vehicles for the delivery of molecular
therapeutics [18-21].
Combining the advantages of T cells with nanotech-
nology has the potential to generate innovative new
approaches to cancer therapy. Several studies have
demonstrated that T cells may serve as efficient drug
delivery vehicles for the treatment of cancer, including
transport of magnetic particles bearing doxorubicin and
for use in boron neutron capture therapy [22,23]. Here
we have explored whether T cells can be used as AuNP
carriers to increase delivery to tumor sites in vivo using
gold colloidal nanospheres (40-45 nm), comparable in
size to hollow gold nanoshells and gold-gold sulfide
nanoparticles used for PTT. Although gold colloid in
this size range has maximal absorbance in the visible
wavelengths, there are several variants of AuNPs that
are of similar size (25-60 nm) and absorb optimally in
the NIR region, permitting translation of this delivery
method for PTT. These gold nanoparticle variants
include gold-gold sulfide nanoparticles, hollow gold
nanoshells, and gold nanocubes, all of which have
demonstrated efficacy as PTT-mediating agents in
mouse studies [24]. Additionally, there have been studies
demonstrating photothermal therapy using gold colloid
that has been strategically aggregated to red-shift the
peak absorbance into the NIR [25,26]. The possible
applications of a AuNP-T cell delivery system could
further be extended to imaging and drug delivery appli-
cations, as gold nanoparticles also have demonstrated
potential as scatter- and absorption-based imaging con-
trast agents [27-30] and drug delivery agents [31]. In
this study, we demonstrate that gold colloid is readily
taken up by activated human T cells without impairing
their viability or cellular functions, and that following
intravenous infusion into tumor bearing micecan more
efficiently deliver AuNPs to distant tumor sites.
Results
Loading of activated human T cells with AuNPs
Synthesized gold colloid was determined to be 40-45
nm in diameter by transmission electron microscopy
(TEM) (Figure 1a and Figure S1 in Additional file 1).
Activated and expanded human T cells were cultured
in the presence of AuNPs for a period of 1 to 24 h to
permit AuNP internalization. AuNP loading was con-
firmed using bright field and dark field microscopy
demonstrating that T cells co-localize with AuNPs
(Figure 1b). We further optimized loading conditions
by altering AuNP concentration (per cell) and time of
incubation. To determine the number of nanoparticles
present per T cell, an inductively coupled plasma opti-
cal emission spectrometry (ICP-OES) analysis was
used. T cells from three different human donors were
first cultured with concentrations of AuNPs ranging
from 0.05 to 0.5 nM for a period of 24 h to evaluate
for variability in gold nanoparticle loading due to dif-
ferences in T cells from different donors (Figure 1c). A
maximum of 14,900 ± 2,400 AuNPs was internalized
per T cell using a AuNP loading concentration of 0.5
nM (Figure 1c). We then performed a time course
study using T cells from a single donor to determine
the minimum amount of time required to load the T
cells with the maximum number of AuNPs (Figure
1d). For this study, we incubated T cells with nanopar-
ticle concentrations ranging from 0.05 to 1 nM. At 24
h, the 0.5 and 1 nM groups have similar gold content,
suggesting that there is a maximum amount of AuNPs
that can be internalized by T cells. These results
demonstrate that maximal AuNP loading of T cells
can be achieved using a concentration of 0.5 nM
AuNP and an incubation period of 24 h.
AuNP-loading does not affect T cell viability or function
We next measured T cell viability and function post-
AuNP loading to assess potential toxicity that may inhi-
bit T cell performance as an in vivo delivery vehicle.
Loading T cells with AuNPs had no immediate effect on
T cell viability as determined by Annexin-V/7-AAD
staining (Figure 2a) and did not alter the phenotype of
the cells (Figure S2 in Additional file 1). Furthermore,
there were no prolonged effects on T cell proliferation
as measured by thymidine incorporation (Figure 2b).
Importantly, AuNPs did not affect migration when
tested in a transwell chemotaxis assay against superna-
tant produced from human LCL tumors, suggesting that
T cells retain their migratory behavior post-AuNP
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ing mitogen activation (PMA-I) was not impaired by
AuNPs (Figure 2d). These results show that AuNPs
have no detrimental effects on T cell viability and func-
tion in vitro and indicate that T cell migration in vivo
will likely be retained following loading.
T cells migrate and transport AuNPs to tumors in vivo
In vivo AuNP-T cell migration to tumor sites was first
examined using bioluminescent imaging and histology.
T cells were first genetically modified to express firefly
luciferase and then subsequently loaded with AuNPs.
Bioluminescent imaging 48 h post-intravenous injection
of AuNP-T cells demonstrate specific migration of the
T cells to subcutaneous LCL tumors in immune defi-
cient SCID mice (Figure 3a). This timepoint was
selected based on previous studies that have demon-
strated T cell localization to tumor sites 48 h post-infu-
sion [32,33]. We next resected the tumors and
performed histology to determine if AuNPs and T cells
co-localized within the tumor. Immunohistochemical
staining using CD3 antibody (a pan-T cell marker)
demonstrated infiltration of T cells into the tumor (Fig-
ure 3b). In addition, areas of increased scatter in the
darkfield images correlated well with areas of CD3
+
staining. This observation demonstrates that the T cells
maintain internalized AuNPs during in vivo migration
to the tumor site.
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Figure 1 Gold nanoparticle uptake by human T cells. (A) TEM imaging of gold colloid (diameter = 40-45 nm). (B) Brightfield (upper) and
darkfield (lower) images of human T cells demonstrate gold nanoparticle uptake by the increased light scattering seen in the AuNP-T cell group
compared to T cells alone. (C) ICP-OES analysis of T cell gold content at 24 h using different nanoparticle loading concentrations. Each point is a
composite of data acquired from three different T cell donors. (D) Time course data for T cells from a single donor loaded with different
concentrations of gold nanoparticles. Optimal loading occurred after 24 h at a concentration between 0.5 and 1.0 nM.
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biodistribution
We next performed a comprehensive in vivo biodistribu-
tion study using inductively coupled plasma mass spec-
trometry (ICP-MS) and ICP-OES to map the location of
free PEGylated AuNPs (40-45 nm gold colloid coated
with 5000 MW PEG) and AuNPs delivered by T cells.
Prior to injection, ICP-OES was performed to determine
the absolute gold dose for PEG-AuNPs and AuNP-T
cells. Following intravenousi n j e c t i o nw i t hP E G - A u N P s
or AuNP-T cells, tumors, and organs (bone, brain,
heart, intestine, kidney, liver, lungs, muscle, plasma, and
spleen) were harvested and analyzed for gold levels
using ICP-MS. For PEG-AuNP treated mice, organs
were harvested at 4, 8, 24, and 48 h post-injection, while
for AuNP-T cell treated mice, organs were harvested at
24 and 48 h (Figure 4a). Predictably, the biodistribution
of AuNP-T cells is altered when compared to that of
the PEG-AuNPs. As observed in previous studies
[13,15], the highest percentages of AuNPs using PEG
coating were delivered to the liver and spleen (5.65 and
17.03%, respectively, at 48 h, Figure 4b,c). In compari-
son, T cells delivered AuNPs to the lung, liver, and
spleen, which received 4.76, 33.5, and 2.69% at 48 h,
respectively (Figure 4b and 4c). The plasma half-life of
the PEG-AuNPs was calculated to be 6.05 h, and no
gold was detected in the plasma for the AuNP-T cell
group, suggesting no significant AuNP leakage from the
T cells during in vivo migration. The AuNP-T cell bio-
distribution over time correlates with the normal biodis-
tribution of human T cells, suggesting that the presence
of internalized AuNPs does not significantly change the
T cell biodistribution [32]. These data suggest that cellu-
lar delivery of AuNP will result in a unique biodistribu-
tion pattern that is dependent on the cell type used for
delivery.
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Figure 2 AuNP loading has no significant effect on T cell viability or function. T cells were loaded in the presence of 0.5 nM AuNPs for 24
h or cultured in medium alone and then measured for viability using Annexin-V/PI staining (A), proliferation using thymidine incorporation (B),
migration through a transwell membrane in response to tumor (LCL) produced supernatant (C) and intracellular analysis of IFN-g cytokine
production following mitogen stimulation (D).
Kennedy et al. Nanoscale Research Letters 2011, 6:283
http://www.nanoscalereslett.com/content/6/1/283
Page 4 of 11T cell delivery increases tumor accumulation of AuNPs
Closer examination of LCL tumors following treatment
with either PEG-AuNPs or AuNP-T cells showed an
increase in AuNP delivery to tumors following cellular
transport. For PEG-AuNPs, the highest level of accumu-
lation in tumors was observeda t2 4hp o s t - i n j e c t i o n ,
while peak tumor gold accumulation following T cell
delivery was seen at 48 h. Using PEG-AuNP, ICP-MS
analysis of gold content of excised tumor tissue showed
that 0.39 ± 0.33% of ID reached the tumor at 24 h.
Whereas, using AuNP-T cells, 1.55 ± 0.72% of the ID
localized to the tumor at 48 h (P < 0.01) (Figure 5).
This represents a four-fold increase in the efficiency of
AuNP delivery to the tumor site using T cells as
vehicles.
Discussion
One of the greatest challenges of translating nano-
technologies to the clinical realm is optimizing in vivo
delivery. Maximizing AuNP accumulation at the tumor
site has the potential to enhance photothermal cancer
therapy, as well as other applications such as optical ima-
ging. In this study, we show that human T cells can be
used to transport AuNPs to distant tumor sites following
intravenous administration. Following short term incuba-
tion with AuNPs, T cells can be efficiently loaded with
over 14,000 AuNPs per cell without affecting cell viabi-
lity, proliferation, and cytokine production. Importantly,
T cells loaded with AuNPs retain their ability to migrate
in vitro, and demonstrate tumor-specific homing in mice.
Using T cells as a vehicle to deliver AuNPs resulted in a
four-fold increase in the efficiency of AuNP tumor accu-
mulation, demonstrating that active transport of AuNPs
by cellular chaperones is superior to that of passive accu-
mulation through the EPR effect.
Stephan et al. [33] recently demonstrated that syn-
thetic drug-carrier nanoparticles could be stably conju-
gated to the surface of immune cells, including T cells,
for delivery of therapeutic molecules. In these studies, T
cells efficiently carried surface-tethered nanoparticles to
tumors in mice, and when loaded with cytokines to sup-
port T cell growth, dramatically increased antitumor
efficacy. However, our study conclusively demonstrates
in vivo that internal loading of AuNPs in T cells can
improve tumor localization, and thus may be a useful
technology for a variety of nanoparticle based therapies.
In this study, we elect to use AuNPs. AuNPs are known
to have low cytotoxicity, and gold has been used in
humans for the treatment of arthritis for over 50 years
[34], which makes AuNPs a logical choice in the pursuit
of clinical applications. For this study, 40-45 nm gold col-
loidal nanospheres were selected for internalization by
activated human T cells. The internalization of nanopar-
ticles by cells is believed to be accomplished predomi-
nantly by receptor-mediated endocytosis, and particle
size is an important variable in determining the kinetics
b a
123 123
PBS AuNP-T cells
IHC - CD3 IHC - CD3
DF DF
Figure 3 AuNP-loaded T cells migrate to tumors in vivo. (A) T cells were retrovirally modified to express firefly luciferase then loaded in the
presence of 0.5 nM AuNP for 24 h. Cells were subsequently injected intravenously into SCID mice bearing subcutaneous xenografted LCL
tumors. Bioluminescent imaging of AuNP-T cell biodistribution at 48 h post-injection showing AuNP-T cell localization at the tumor site (red
circle) and within the spleen. (B) Resected tumors were analyzed by bright field imaging (top row) and immunohistochemistry for human CD3
expression and dark field imaging (bottom row) to indicate the presence of AuNPs. Red arrows indicate the colocalization of CD3
+ T cells and
AuNPs within the tumor.
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Page 5 of 11of cellular uptake, with maximal uptake in a size range of
40-50 nm [35,36]. We selected the size of our AuNPs for
this proof-of-concept delivery study to optimize nanopar-
ticle cellular uptake. We modulated the degree of nano-
particle internalization by altering the concentration of
nanoparticles incubated with the T cells (Figure 1c). We
also evaluated nanoparticle uptake using T cells isolated
from three different human donors (Figure 1c) and saw
only small variation, suggesting that this technique could
be extrapolated to the T cells of any patient.
The internalized gold collo i du s e di nt h i ss t u d ya l s o
had no detrimental impact on the viability or function
of activated human T cells in vitro (Figure 2), and the T
cells were able to migrate to tumors in vivo while main-
taining their AuNP payload (Figure 3). In addition to
their ability to carry AuNPs to tumors, T cells can be
selected for tumor-specificity for adoptive immunother-
apy studies [37-39]. Furthermore, T cells may be geneti-
cally engineered to improve their function [40,41] or
enhance their ability to migrate to tumors in vivo
[42,43]. It has been demonstrated that systemically
administered AuNPs tend to accumulate mainly in the
perivascular regions of the tumor [11], limiting passive
accumulation of nanoparticles by the EPR effect to well-
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Figure 4 Biodistribution comparison of AuNPs and AuNP-T cells in mice. Mice were injected with PEG-AuNPs (60-65 nm hydrodynamic
diameter), AuNP-T cells, or PBS and subsequently sacrificed at various time points to determine biodistribution. PBS gold levels were negligible
in comparison to AuNP and AuNP-T cell groups for all organs. Values are percentage of the injected gold dose (%ID) were calculated from ICP-
MS and are normalized for dry weight differences. The AuNP-T cell group exhibited significantly higher gold delivery to the lungs, liver, and
bone, while the AuNP group demonstrated higher gold levels within the small intestine. No significant differences were seen in the spleen,
kidney, muscle, or brain. An asterisk indicates statistically significant (P < 0.05) differences.
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Page 6 of 11vascularized regions of the tumor. T cells may naturally
localize to tumors, and tumor-specific T cell clones have
been demonstrated to penetrate into the hypoxic cores
of the tumors in vivo [44]. The more extensive infiltra-
tion of tumor sites by antigen-specific T cells may per-
mit enhanced penetration of the tumor when compared
to freely-injected nanoparticles, potentially augmenting
therapeutic efficacy.
The use of T cell vehicles also significantly affects
nanoparticle biodistribution (Figure 4). Freely injected
nanoparticles (40-45 nm gold colloidal nanospheres
coated with 5000 MW PEG) accumulate most signifi-
cantly in well-vascularized organs such as the liver,
spleen, kidney, and gut (Figure 4). Maximal AuNP
tumor accumulation for the freely injected PEG-AuNP
group is seen at 24 h (Figure 5). After 24 h, increased
gold content for the PEG-AuNP group is seen in the
spleen, liver, and kidney with a corresponding decrease
in gold content within the tumor and other organs,
which represents a shift towards AuNP clearance.
AuNP-T cells present a much different biodistribution
from the systemically administered nanoparticles that
correlates with the expected biodistribution of T cells.
After adoptive transfer of AuNP-T cells, a large percen-
tage of the ID is seen within the liver and lungs at 24 h.
T cells are known to accumulate within the liver and
lungs after administration due to the vascularity and
number of adhesion molecules present in these organs
[45]. This pattern of T cell migration is consistent with
the biodistribution of adoptively transferred T cells seen
in previous studies [33,45]. AuNP-T cells are also seen
accumulating in the spleen and bone of the mice; these
locations are also normal reservoirs of T cells [46]. The
large number of AuNP-T cells seen in the liver likely
represents apoptotic T cells. This large accumulation is
not observed by bioluminescence imaging in Figure 3,
and the liver is a known site where apoptotic T cells are
entrapped [47]. Tumor accumulation of AuNP-T cells
increases from 24 to 48 h as T cells escape from the
lungs and migrate to the tumor (Figure 5). The biodis-
tribution of AuNP-T cells matches the expected biodis-
tribution of normal activated T cells, suggesting that
AuNP biodistribution can be modulated based on the
selection of the cellular vehicle. In the case of T cells, it
is possible that the biodistribution may be altered to to
further favor tumor accumulation and persistence by
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Figure 5 AuNP-T cells enhance the delivery of gold nanoparticles to the tumor site in vivo. Tumor-bearing mice were injected i.v. with
PEG-AuNPs or AuNP-T cells. Tumors were subsequently resected at various time points and measured for AuNP content using ICP-MS. Values
displayed represent the percentage of injected gold normalized for tumor dry weight differences (mean ± SEM). The percentage of gold
delivered by the AuNP-T cells at 48 h represents a significant, four-fold increase over the PEG-AuNP group at 24 h (P < 0.01).
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Page 7 of 11manipulating cell culture conditions [45] or by genetic
modification of T cells [43].
Using T cells as cellular vehicles for AuNP delivery,
we achieve a four-fold increase in tumor delivery effi-
ciency at 48 h when compared to freely injected PEG-
coated AuNPs at 24 h (Figure 5). This represents a sig-
nificant increase in delivery efficiency (P <0 . 0 1 ,S t u -
dent’s t-test) using T cells. These results demonstrate
for the first time that T cells can be used to enhance
AuNP delivery to a tumor in vivo. The use of AuNPs
and T cells together combines the photothermal therapy
and imaging advantages of AuNPs with the immu-
notherapy and biodistribution advantages of T cells.
Future directions will focus on utilizing the AuNP-T
cell system for cancer therapy by modifying the T cells
to further enrich AuNP tumor accumulation and
enhance anti-tumor effects.
Conclusions
I nt h i ss t u d yw ed e m o n s t r a t et h ei n t e r n a l i z a t i o no f
AuNPs into activated human T cells for the delivery of
nanoparticles in vivo. AuNP uptake has no negative
impact on T cell viability, proliferation, or immune
function, and T cells are able to transport the AuNP
payload to tumor sites in vivo. Furthermore, the use of
T cells as a AuNP vehicle enhances in vivo delivery effi-
ciency by four-fold. This delivery method alters the bio-
distribution of gold compared to freely injected AuNPs,
and demonstrates that the selection of a particular cellu-
lar vehicle may dictate AuNP biodistribution.
Methods
AuNP synthesis and PEGylation
Gold(III) chloride trihydrate (HAuCl4 3H2O 99%) and
potassium carbonate anhydrous (K2CO3 99%) were pur-
chased from Sigma-Aldrich (S t .L o u i s ,M O ) .D e i o n i z e d
water was provided by a Milli-Q system. In this synth-
esis method, Au
3+ is reduced to Au
0 u s i n gC Oa sa
reducing agent. A 0.38 mM HAuCl4 solution was pre-
pared and aged in an amber bottle at 4°C for a mini-
mum of 72 h prior to use. After aging the chloroauric
acid solution, the temperature was allowed to gradually
rise to 16°C. A 1.8 mM K2CO3 solution was then pre-
pared by adding 75 mg of K2CO3 to the aged 200 mL
HAuCl4 solution. This solution was aged for 30 min
prior to aeration with CO gas. A 40 mL volume of the
aged solution was added to the beaker and stirred con-
tinuously prior to aeration. CO gas (Matheson-Trigas)
was injected into the continuously stirring solution at a
flow rate of 30.5 mL/min. The CO flow was controlled
via a flow rate control valve. A visible color change
from clear to dark purple to red is observed during
synthesis, indicating formation of AuNPs. TEM images
were taken to confirm size and monodispersity. Particles
were sterilized by filtration through a 0.22 μmp o l y -
ethersulfone filter. To stabilize the particles in prepara-
tion for mouse injection, 0.5 mM polyethylene glycol-
thiol (PEG-SH, MW = 5 kD, Nektar) was added to the
particles. After a 24-h incubation, excess PEG-SH was
removed by centrifugation and PEGylated particle stabi-
lity was confirmed by increasing solution tonicity with 1
M NaCl. Dynamic light scattering measurements were
taken to assess the hydrodynamic diameter of the PEGy-
lated gold colloid.
T cell isolation and preparation
Peripheral blood was obtained with informed consent
from willing healthy donors using a Baylor College of
Medicine Institutional Review Board approved protocol.
Peripheral blood mononuclear cells (PBMC) were iso-
lated by Ficoll gradient centrifugation (Lymphoprep,
Nycomed, Oslow, Norway). PBMC were used to gener-
ate EBV-transformed B cells lines (LCL) and T cell
lines. LCL and T cells were maintained in RPMI 1640
supplemented with 10% fetal calf serum (FCS; Hyclone,
Logan, UT) and 2 mM GlutaMAX (Invitrogen, Carlsbad,
CA). For T cell expansion, non-tissue culture treated 24-
well plates were coated with OKT3 (1 μg/mL; Ortho
Pharmaceuticals, Raritan, NJ) and anti-CD28 antibody (1
μg/mL; BD Biosciences, San Diego, CA) overnight at 4°
C. Plates were washed and 2 × 10
6 PBMC were plated
per well in complete RPMI supplemented with 100 U/
mL recombinant human interleukin-2 (IL-2). On day 3,
T cell blasts were harvested and further expanded or
transduced in IL-2 supplemented media.
T cell internalization of AuNPs
Day 7 OKT3 blasts were harvested and suspended in
complete RPMI supplemented with IL-2 and 0, 0.05,
0.1, 0.25, 0.5, or 1 nM of AuNPs for 24 h (1 mole =
6.022 × 10
23 nanoparticles). Cells were harvested and
washed a minimum of three times using 1 × phosphate-
buffered saline (PBS) prior to subsequent experiments.
To confirm loading, T cells were imaged using darkfield
microscopy. To quantitatively characterize loading, 2 ×
10
6 T cells per sample were prepared for ICP-OES ana-
lysis by digesting the cells in three parts trace metal
grade hydrochloric acid (Fisher Scientific, Pittsburgh,
P A )a n do n ep a r tt r a c em e t a l grade nitric acid (EMD
Chemicals, Gibbstown, NJ) overnight. Samples were
then diluted to 10 mL in distilled water and filtered. T
cells incubated with media alone were used as a control.
T cell viability and functionality after AuNP loading
To determine the effect of AuNP loading on T cell phe-
notype, we used the following monoclonal antibodies
conjugated to FITC, PE, PerCP, or APC (BD Bios-
ciences): CD3, CD4, CD8, CD45RA, CD45RO, CD56,
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Page 8 of 11CD62L, CCR5, and CCR7. An Annexin V apoptosis
detection kit (BD Biosciences) was used to determine T
cell viability post-AuNP loading. Cells were analyzed
using a FACSCalibur flow cytometer (BD Biosciences)
and FCSExpress software (De Novo Software, Los
Angeles, CA). A [
3H] thymidine incorporation assay was
used to assess the effects of AuNP loading on T cell
proliferation. Following AuNP loading, T cells were
seeded in triplicate into 96-well round bottom plates at
1×1 0
5 cells per well in complete RPMI containing 100
U/mL IL-2 for 24 h. T cells were then pulsed with 5
μCi [
3H] thymidine (Amersham Pharmacia Biotech, Pis-
cataway, NJ) overnight. Cells were then harvested onto
glass filter strips and analyzed using a TriCarb 2500 RT
b-counter (Packard Biosciences, Downers Grove, IL). To
determine if AuNP-loaded T cells retain the ability to
migrate in vitro, we used a transwell migration assay. T
cells were labeled with 50 μCi Chromium
51 (Cr
51; MP Bio-
medicals, Solon, OH) and 1.5 × 10
5 cells were placed in
the upper chamber of 24-well 6.5 mm diameter, 5 μm
pore size transwell chambers (Costar Transwell, Corning,
NY). Media alone or LCL tumor supernatant was placed
in the bottom chamber. Plates were then incubated for 3 h
at 37°C. Cells in the bottom chamber were then harvested
and analyzed using a g-counter (Cobra Quantum, Perkin
Elmer, Shelton, CT). Specific migration was calculated
using the following equation: Specific Migration (%) =
(Experimental [LCL supernatant] - Spontaneous [media
alone])/(Maximum [1.5 × 10
5 cells] - Spontaneous [media
alone]) × 100. To measure the ability of AuNP-loaded T
cells to secrete IFN-g following mitogenic stimulation, 2 ×
10
5 T cells were seeded into 96-well round bottom plates
for 24 h. T cells were then stimulated with 25 ng/mL
phorbol myristate acetate (PMA; Sigma-Aldrich, St. Louis,
MO) and 1 μg/mL Ionomycin (I; Sigma-Aldrich). Follow-
ing 2 h of PMA-I stimulation, Brefeldin A (Sigma) was
added to allow for intracellular cytokine retention. Four
hours later, cells were permeabilized using 1% Saponin
(Sigma) and IFN-g expression was detected by intracellular
cytokine staining using PE-conjugated anti-IFN-g mono-
clonal antibody (BD Biosciences).
In vivo delivery studies
SCID xenograft model
In vivo migration, AuNP delivery, and biodistribution
studies were performed using severe combined immune
deficient mice (SCID [strain ICR-Prkdc(scid)]; Taconic,
Hudson, NY). All mouse experiments were performed
under a Baylor College of Medicine Institutional Animal
Care and Use Committee (IACUC) approved protocol. 1
×1 0
7 LCL tumor cells were resuspended in Matrigel
(BD Biosciences) and injected subcutaneously (s.c.) into
the shaved right flanks of mice. Tumors were allowed to
establish and grow to at least 0.5 mm × 0.5 mm in size
(2-3 weeks) before use.
Mouse injections and sample collection
To prepare AuNP-T cell injections, T cells were pre-
pared as above and incubated with 0.5 nM AuNPs for
24 h. Cells were harvested and washed extensively using
1 × PBS prior to injection. For delivery studies, mice
received either PBS, 1 × 10
7 AuNP-T cells, or 1 × 10
11
PEGylated AuNPs via the tail vein in a 200 μLb o l u s .
These dosages were selected based on previous in vivo
studies using AuNPs and adoptively transferred T cells.
To determine optimal time points for delivery analysis,
tumors were resected at either 4, 8, 24, or 48 h for the
PEGylated AuNP group and 24 or 48 h for the AuNP-T
cell group. In addition, plasma as well as portions of the
liver, spleen, kidneys, small intestine, muscle, heart,
lung, bone, and brain were also collected for analysis at
4, 8, or 24 h for the PEGylated AuNP group and 24 or
48 h for the AuNP-T cell group. All tissues, including
tumors, were flash frozen with liquid nitrogen after col-
lection and stored at -80°C until analysis.
Bioluminescent imaging
To determine if AuNP-loaded T cells can migrate to
tumors in vivo and thereby deliver AuNP to the tumor
site, T cells were transduced with retrovirus encoding
GFPluc as previously described by our group [48].
Transduced cells were then loaded with AuNPs for 24 h
then injected intravenously (i.v.) via the tail vein (1 ×
10
7 T cells per mouse). Forty-eight hours post-T cell
infusion, the biodistribution of T cells was visualized
using the In Vivo Imaging System (IVIS; Xenogen) fol-
lowing intraperitoneal (i.p.) injection of 150 mg/kg D-
luciferin (Xenogen, Alameda, CA).
Ex vivo tissue analysis and imaging
To image AuNP-T cells within the tumor, tumors were
thawed in a 37°C water bath and embedded in optimal
cutting temperature (O.C.T.) compound (Sakura Finetek
USA, Inc., Torrence, CA) using dry ice. The embedded
tissue was then sectioned into 8 μms l i c e su s i n gac r y o -
stat, dried overnight at room temperature, and stored at
-80°C. Tissue sections were then fixed with acetone and
stained for CD3 using anti-CD3 (Abcam ab5690, Cam-
bridge, MA) as the primary antibody and the Invitrogen
Histostain
® Plus Broad Spectrum (AEC) kit. Slides were
coverslipped with immunomount (Thermo Scientific,
P i t t s b u r g h ,P A )a n di m a g e db yb r i g h tf i e l da n dd a r k
field microscopy. Resected mouse tissues were prepared
a n da n a l y z e df o rg o l dc o n t e n tu s i n gI C P - M Sa n dI C P -
OES. Samples were lyophilized and weighed, then
digested and prepared as previously described. Samples
of the AuNP-T cell and AuNP boluses were also ana-
lyzed to confirm the amount of gold systemically
administered.
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For the biodistribution analysis, we performed a one-way
ANOVA followed by Tukey’s method. Each organ was
examined individually at various time points for each
treatment group (n = 3 for all time points and treatment
groups). Significance was set at P < 0.05. An asterisk indi-
cates significant differences between every possible
AuNP:AuNP-T cell comparison pair at all time points for
each organ. For the tumor delivery analysis, we used a
Student’s t-test to compare AuNP systemic administra-
tion to AuNP-T cell delivery. For this study, n =8f o rt h e
AuNP group, while n = 11 for the AuNP-T cell group.
Additional material
Additional file 1: Figure S1 Gold colloid size distribution. Particle
sizes were determined using TEM. A total of 585 particles were examined
over multiple images to generate the histogram. Figure S2 AuNP-
loading does not affect T cell phenotype. T cells were loaded in the
presence of 0.5 nM AuNP for 24 h and subsequently stained with a
panel of antibodies and analyzed by flow cytometry.
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